Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality globally[1]. Elevated levels of low-density lipoprotein cholesterol (LDL-C) are a well-recognized causal factor, and a substantial body of evidence demonstrates that lowering LDL-C leads to significant reductions in mortality and major adverse cardiovascular events[2]. To achieve deeper LDL-C reductions, attention has turned to proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of LDL receptor (LDL-R) degradation.
